Sector News

Valeant may raise Allergan bid, says it won’t walk away

October 20, 2014
Life sciences
(Reuters) – Valeant Pharmaceuticals Inc (VRX.TO) may raise its hostile takeover bid for Allergan Inc (AGN.N) and will not walk away from its pursuit ahead of Allergan’s Dec. 18 special shareholder meeting, Chief Executive Michael Pearson said on Monday.
Pearson also said speculation that Valeant’s relationship was strained with Pershing Square Capital Management, Allergan’s biggest shareholder, is false.
(Reporting by Rod Nickel in Winnipeg, Manitoba Editing by W Simon)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]